PCM
CNTA

Pinz Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Pinz Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-900
Closed -$20K – 191
2021
Q2 		$20K Buy
+900
New +$21.2K 0.01% 358

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Pinz Capital Management's CNTA Position: Q3 2021 in Review

Pinz Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q3 2021, closing a stake of 900 shares — an estimated $20K sold.

Pinz Capital Management first reported a position in CNTA in Q2 2021 and held it in 1 quarter. The position peaked at $20K in Q2 2021. 40 funds tracked by Wall St. Rank hold CNTA as of Q3 2021.

  • Pinz Capital Management reported no remaining Centessa Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 900 Centessa Pharmaceuticals shares in Q3 2021, an estimated $20K.
  • Pinz Capital Management first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Pinz Capital Management's Centessa Pharmaceuticals position peaked at $20K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.